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Bovine conglutinin, the first animal collectin to be discovered, is structurally very similar to
Surfactant Protein D (SP-D). SP-D is known to interact withMycobacterium tuberculosis,
and the closely-related M. bovis, the causative agent of bovine tuberculosis. We
speculated that due to the overall similarities between conglutinin and SP-D, conglutinin
is likely to have a protective influence in bovine tuberculosis. We set out to investigate
the role of conglutinin in host-pathogen interaction during mycobacterial infection.
We show here that a recombinant truncated form of conglutinin (rfBC), composed
of the neck and C-type lectin domains, binds specifically and in a dose-dependent
manner to the model organism Mycobacterium bovis BCG. rfBC showed a significant
direct bacteriostatic effect on the growth of M.bovis BCG in culture. In addition, rfBC
inhibited the uptake ofM. bovis BCG by THP-1 macrophages (human monocyte lineage
cell line) and suppressed the subsequent pro-inflammatory response. Conglutinin
is well-known as a binder of the complement activation product, iC3b. rfBC was
also able to inhibit the uptake of complement-coated M. bovis BCG by THP-1
macrophages, whilst modulating the pro-inflammatory response. It is likely that rfBC
inhibits the phagocytosis of mycobacteria by two distinct mechanisms: firstly, rfBC
interferes with mannose receptor-mediated uptake by masking lipoarabinomannan
(LAM) on the mycobacterial surface. Secondly, since conglutinin binds iC3b, it
can interfere with complement receptor-mediated uptake via CR3 and CR4, by
masking interactions with iC3b deposited on the mycobacterial surface. rfBC
was also able to modulate the downstream pro-inflammatory response in THP-1
cells, which is important for mobilizing the adaptive immune response, facilitating
containment of mycobacterial infection. In conclusion, we show that conglutinin
possesses complement-dependent and complement-independent anti-mycobacterial
activities, interfering with both known mechanisms of mycobacterial uptake
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by macrophages. As mycobacteria are specialized intracellular pathogens, conglutinin
may inhibit M. bovis and M. tuberculosis from establishing an intracellular niche within
macrophages, and thus, negatively affect the long-term survival of the pathogen in the
host.
Keywords: complement, conglutinin, mycobacterium, phagocytosis, macrophage, bovine tuberculosis, BCG,
cytokine
INTRODUCTION
Conglutinin is a C-type lectin (collectin) that is uniquely found
in Bovidae species (e.g., cattle, Bos taurus) (1). Collectins
are a key group of innate immune molecules which share
a common overall structure, characterized by oligomerization
of a polypeptide which contains a C-terminal carbohydrate
recognition domain (CRD) attached to an N-terminal collagen-
like region via an α-helical coiled neck region (2). Collectins are
soluble pattern recognition receptors (PRR) that can recognize a
variety of microbial ligands, via pathogen-associated molecular
patterns (PAMPs), allergens and other host molecules leading to
clearance through phagocytosis (and for some collectins, through
complement activation) (3). Members of the collectin family
include surfactant proteins A (SP-A) and D (SP-D), mannose
binding lectin (MBL), a number of bovine collectins (conglutinin,
CL-1, CL-P1, CL-43, and CL-46) and several lesser known
proteins (2). Conglutinin has close structural similarities to SP-
D, being able to formmultivalent cruciform structures (tetramers
of trimers) containing in total 12 CRD regions that can bind
to microbial surfaces in the presence of Ca2+ (2). Conglutinin
is secreted largely by the liver and is found in bovine serum at
a concentration of 12µg/ml (4). In contrast, SP-D is primarily
found in the lungs at a concentration of 0.1–0.9µg/ml and is
secreted by alveolar type II cells and Clara cells (5). Conglutinin
is thought to have evolved in the Bovidae from a gene duplication
event of an ancestral SP-D gene and is located on chromosome
28 in B. taurus (analogous to chromosome 10 in Homo sapiens),
proximal to the bovine SP-D gene (6).
The precise biological role of conglutinin is still not fully
understood. Low levels of conglutinin have been observed during
acute infections, such as pneumonia or metritis (7), and among
some cattle breeds that are predisposed to respiratory infection
(4). Like SP-D, conglutinin has been shown to bind to several
microbes including viruses (e.g., Influenza A and rotavirus)
(8–10), Gram-negative bacteria, such as Escherichia coli and
Salmonella typhimurium (11, 12), as well as lipopolysaccharide
(LPS) (13).
The complement system is a crucial first line of defense
against pathogens and is composed of three pathways: classical,
alternative and lectin pathway, which require different stimuli
for activation. Complement activation results in the formation
of a C3 convertase and the deposition of C3b on target surfaces
Abbreviations: TB, tuberculosis; BCG, Bacillus Calmette-Guerin; CR,
complement receptors; MAC, membrane attack complex; PRR, pattern
recognition receptors; PAMP, pathogen-associated molecular patterns; BC,
bovine conglutinin.
which can trigger opsonization and other immunoregulatory
functions. Conglutinin has the unique ability to bind to iC3b (a
proteolytically cleaved form of complement cleavage fragment
C3b), due to its specific affinity for mannose oligosaccharides
on the α-chain of iC3b, which become exposed when C3b is
cleaved (14). Conglutinin has been shown to bind to iC3b-
coated erythrocytes, resulting in their agglutination (14, 15), to
yeast mannan (16), and to iC3b-coated E. coli, enhancing the
respiratory burst of phagocytes (11). Other collectins can also
mediate interactions between microbes and phagocytes. SP-A
and SP-D have been shown to bind to several bacteria, virus
and fungi and influence their uptake by phagocytes (17). In
contrast, the anti-microbial properties of conglutinin in this
regard remain to be more fully explored. Conglutinin has been
observed to strongly inhibit hemagglutination and infectivity of
Influenza A virus, causing agglutination of viral particles and
also to act as an opsonin, enhancing phagocytic responses against
the virus (8, 18). Furthermore, conglutinin has protective activity
in vivo, where its sub-cutaneous injection increased the survival
of mice experimentally infected with highly virulent strains of
S. typhimurium (12). Similarly, MBL, SP-D, and SP-A have also
been shown to be protective in vivo (19).
A major infection of the bovine host is bovine tuberculosis,
and, it is, therefore, of great importance to investigate what
role conglutinin plays in its pathogenesis. In cattle, bovine
tuberculosis accounts for substantial economic cost and presents
a risk of human infection (20–23). The causative agent,M. bovis,
can also cause infection in a wide variety of mammals including
wildlife e.g., Eurasian Badgers (Meles meles) (22), which are
thought to be a reservoir for bovine tuberculosis infection in
cattle. We have previously shown that complement activation
can occur on M. bovis BCG via the classical, alternative and
lectin pathways, which results in the deposition of C3b and iC3b
on the mycobacterial surface (24). Mycobacteria are specialized
intracellular pathogens that have evolved to survive and persist
within phagocytes and its major consequence is latent infection
(25). Complement deposition on the surface of M. tuberculosis
has also been shown to enhance its phagocytosis by macrophages
and that this is mediated by complement receptors on the
host cell surface (26–31). Similarly, SP-D was found to bind
to M. tuberculosis and inhibit its uptake by macrophages via
the mannose receptor on the host cell (32). We find these two
observations on M. tuberculosis intriguing, given the known
similarities of conglutinin to SP-D and the ability of conglutinin
to bind iC3b.
In the present study, we have set out to investigate the role of
conglutinin in M. bovis infection. There is very little published
work on this topic. One paper reports that conglutination
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(erythrocyte-agglutination by conglutinin) activity in bovine
serum decreased in responses to M. bovis infection in cattle
(33). We have used a recombinant form of truncated bovine
conglutinin (rfBC), composed of the α-helical neck region
and the CRD of conglutinin (13) to investigate the binding
of conglutinin to the vaccine strain M. bovis BCG (a model
organism for M. bovis) and its effect on THP-1 macrophages (a
model cell line for phagocytes). We show that rfBC binds to M.
bovis BCG in a complement dependent as well as independent
manner, and interferes with uptake of the bacterium by THP-
1 cells. We also show evidence of an altered pro-inflammatory
response, which is likely to influence the subsequent adaptive
immune response that is crucial in tuberculosis pathogenesis.
Thus, we provide the first fundamental data on the role of
conglutinin in mycobacterial infection and its complement
dependent and independent interactions, showing its ability to
interfere with two major mechanisms of pathogen uptake by
macrophages.
MATERIALS AND METHODS
Expression and Purification of a Truncated
Form of Recombinant Bovine Conglutinin
(rfBC)
A recombinant polypeptide composed of the neck and the CRD
regions of bovine conglutinin was expressed in Escherichia coli,
and purified, as previously described (13). This preparation
consists of amino acid residues 197–351 of the mature protein
and has an expected monomer molecular weight of about 23
kDa (13). Endotoxins were removed using a polymyxin B column
(Sigma-Aldrich). The levels of endotoxin in the purified protein
was measured using chromogenic Limulus Amebocyte Lysate
(LAL) endotoxin assay kit (GenScript), and found to be<5 pg/µg
of rfBC.
Commercially available recombinant maltose-binding protein
(MBP) (NEB; E8200S) was used a negative control protein.
Western Blotting
Following 12% v/v SDS-PAGE, the gel was equilibrated in
blotting buffer (12mM Tris, 96mM glycine, 20% methanol,
pH 8.3) and transferred, using a Mini Trans-Blot Cell (Bio-
Rad), onto a PVDF membrane (Thermo Fisher Scientific). The
membrane was then washed in PBS and blocked with low-
fat 5% milk (w/v) in PBS overnight. For immunostaining,
membranes were incubated for 1 h at room temperature with
either rabbit anti-bovine conglutinin IgG antibody (University
of Odense, Denmark; diluted 1:1,000), or mouse anti-maltose-
binding protein (MBP) monoclonal IgG antibody (NEB, E8032S;
1µg/ml, diluted 1:10,000 in PBS, 0.05% Tween 20. Membranes
were then incubated for 1 h with polyclonal goat anti-rabbit
IgG conjugated to horseradish peroxidase (HRP) or rabbit
anti-mouse IgG-HRP conjugate, respectively. (Sigma-Aldrich),
diluted 1:1,000 in PBS, 0.05% Tween 20. Membranes were
developed using ClarityWestern ECL kit (BioRad) and visualized
on a ChemiDocTM XRS+Molecular Imager (BioRad).
Characterization of rfBC Oligomerization
via Chemical Cross-Linking
To confirm that rfBC formed a homotrimeric structure, as shown
in the previous study (13), a chemical cross-linking procedure
was performed using a BS3 [bis(sulfosuccinimidyl)suberate]
(Thermo Fisher Scientific). Aliquots of rfBC protein were made
(100 µl of 20µg/ml) for 8 time-point reactions (0, 1, 2, 4, 8,
16, 32, 64min). 5 µl of 1mM BS3 in dimethyl sulfoxide was
then added to each aliquot and incubated at room temperature.
After incubation, 1M Tris-HCl (pH 7.5) was added to a final
concentration of 20mM to stop the reaction. Cross-linked
proteins were then visualized by SDS-PAGE and Coomassie blue
staining.
Mycobacterial Cell Culture
M. bovis BCG (Pasteur strain; ATCC) was grown in liquid
culture using Middlebrook 7H9 medium (Sigma-Aldrich),
supplemented with 0.2% (v/v) glycerol, 0.05% (v/v) Tween-
80, and 10% (v/v) albumin-dextrose-catalase (ADC) (BD BBL,
Becton Dickinson). Green fluorescent protein (GFP)-expressing
M. bovis BCG (Danish Strain 1331) containing the pGFPHYG2
plasmid (a gift from Dr. B. Robertson, Imperial College London,
UK) was grown in the above medium but with the addition of
50µg/ml of hygromycin to maintain the plasmid. Cultures were
incubated at 37◦C with agitation (∼120 rpm) for 7–10 days until
the bacteria had reached the exponential growth phase (OD600nm
= 0.60–1.00), which is equivalent to 1× 109 bacteria/ml.
THP-1 Cell Culture
THP-1 cell line (derived from a human acute monocyte
leukemia; ATCC TIB-202) was cultured in complete RPMI-1640
(Gibco) (cRPMI) containing 10% (v/v) fetal bovine serum (FBS)
(Sigma-Aldrich), 2mM L-glutamine (Sigma-Aldrich), 100 U/ml
penicillin (Sigma-Aldrich), 100µg/ml streptomycin (Sigma-
Aldrich) and 1mM sodium pyruvate (Sigma-Aldrich) and left to
grow in 5% v/v CO2 at 37
◦C for ∼3 days before passaging. To
count cells and assess cell death, equal volumes of cell suspension
and Trypan Blue (0.4% w/v solution) were mixed and cells were
counted using a haemocytometer with Neubauer rulings.
Assay of rfBC Binding to M. bovis BCG
M. bovis BCG cells, grown to mid exponential growth phase,
were harvested and washed in PBS and the concentration was
adjusted to 1 × 107 cells/ml in PBS. Then, 50 µl of M. bovis
BCG bacterial suspension was dispensed into each well of a 96-
well ELISA plate (MaxisorbTM, Nunc). Plates were incubated at
37◦C for 2 h, or 4◦C overnight and washed once with PBS. Wells
were then blocked for 2 h at 37◦C with PBS containing 1% w/v of
bovine serum albumin (BSA).
rfBC (100µl/well) at various concentrations (0.65, 1.25, 2.5, 5,
10, 20, or 40µg/ml) in buffer I (40mM Tris-HCl, 200mM NaCl,
pH 7.4 containing 5mM CaCl2 or 10mM EDTA) were added to
the coated wells and incubated for 1 h at 37◦C followed by 1 h
at 4◦C. MBP was used a negative control. Microtiter wells were
washed three times in buffer I. Bound proteins were detected
by adding rabbit anti-bovine conglutinin polyclonal antibody or
mouse anti-MBP monoclonal antibody (Sigma-Aldrich) to wells
Frontiers in Immunology | www.frontiersin.org 3 February 2019 | Volume 9 | Article 3159
Mehmood et al. Interaction Between Conglutinin and BCG
containing rfBC or MBP, respectively. Antibody dilutions were
used as described above for Western Blotting. Antibodies were
incubated for 1 h at 37◦C, then wells were washed 3 times with
buffer 1.
To detect the bound antibodies, Protein A-HRP (Sigma-
Aldrich) or rabbit anti-mouse IgG-HRP conjugate were added
to the wells at a dilution of 1:1,000 in PBS and incubated
at 37◦C for 1 h. Wells were then washed three times with
buffer I. The substrate was added (100 µl/well of 3, 3′,5,5′-
Tetramethylbenzidine; TMB) and the plate incubated in the dark
for 1–5min to allow color to develop, which was stopped by
adding 50 µl of 0.5M H2SO4. The optical density at 450 nm
was then measured using (BioRad iMark microplate reader). All
assays were conducted in triplicate.
Maltose-Mediated Inhibition of rfBC
Binding to M. bovis BCG
Microtitre plate wells were coated with M. bovis BCG cells and
then blocked, as described above. 40 µg of rfBC was incubated
with 0, 10, or 100mM maltose in calcium buffer (40mM Tris,
200mM NaCl, 5mM CaCl2 pH 7.4). Samples were incubated for
1 h at 37◦C and, then for 1 h at 4◦C. Binding of rfBC was detected
as described above.
Fluorescence Microscopy to Show Direct
Binding of rfBC to M. bovis BCG
M. bovis BCG cells, grown to mid exponential growth phase,
were harvested by centrifugation at 3,300 × g for 10min and
washed in PBS. The cell pellet containing 2 × 109 bacteria was
then re-suspended in 500 µl of buffer I with 5mM CaCl2. rfBC
(20µg/ml) was then added and gently mixed via pipetting. As a
negative control, a separate tube containing M. bovis BCG was
incubated with MBP (20µg/ml). Proteins were incubated with
M. bovis BCG for 1 h at 37◦C, followed by 1 h at 4◦C with gentle
shaking. Cells were then pelleted by centrifugation and washed
twice in 500 µl of PBS. Rabbit anti-bovine conglutinin or mouse
anti-MBP (dilutions as used for Western blotting) were added
and incubated at 37◦C for 1 h. Cells were washed 3 times in
500µl PBS. Protein A conjugated with fluorescein isothiocyanate
(FITC) (Sigma-Aldrich) (diluted 1:1,000 in PBS) was then added
and incubated for 30min in the dark at room temperature. Cells
were washed 3 times in PBS and the cell pellet, resuspended
in 20 µl of PBS, was spotted onto glass slides and covered
with a coverslip. Slides were analyzed using a Leica fluorescence
microscope (Leica DM4000).
Direct Effect of rfBC on M. bovis BCG
Growth
M. bovis BCG cells were grown to mid exponential growth phase
and 2ml culture were harvested as described above. The cell pellet
containing 2 × 109 bacteria was then resuspended in 1ml of
Middlebrook 7H9 with supplements (see above). Bacteria were
separated into a single cell suspension by passing through a 1ml
syringe with 25-gauge needle 12–15 times to break clumps. Tubes
containing 10-fold serial dilutions of the bacterial suspension
(total of 1ml) were then set up and incubated with 0, 10, 20,
and 40µg/ml of rfBC, in the presence of 5mM CaCl2, for 1 h
at 37◦C, followed by 1 h at 4◦C, with gentle shaking. Tubes were
then vortexed and 200µl of bacterial culture were plated on 7H10
plates, supplemented with 10% OADC and incubated for 2–3
weeks at 37◦C. Bacterial colony forming units (CFU) were then
counted by visual inspection. The experiment was performed in
triplicate for each rfBC concentration and was repeated 3 times.
Propidium Iodide Assay for M. bovis BCG
Viability
M. bovis BCG cells were grown to mid exponential growth
phase and 1ml was harvested, as described above, into each of
five microfuge tubes and washed in PBS. Cell pellets were then
resuspended in buffer I with 5mM CaCl2 and 0, 10, 20, and
40µg/ml of rfBC added to each tube. All tubes were incubated
for 1 h at 37◦C in a shaker followed by one h at 4◦C. Cells were
then pelleted by centrifugation and resuspended in 1ml of PBS.
As a positive control, one additional rfBC-untreated sample was
heated at 100◦C for 10min to lyse the cells. Propidium iodide
(Sigma-Aldrich) was added to each tube (1µg/ml), mixed by
gentle pipetting and incubated for 20min at room temperature in
the dark. After incubation, tubes were centrifuged at 10,000 rpm
for 10min and washed with 500µl of PBS three times. Cell pellets
were then resuspended in 20 µl of PBS and the cell suspension
spotted on a glass slides and covered with a coverslip. Slides were
analyzed using a Leica fluorescence microscope (DM4000). The
assay was performed in triplicate.
Phagocytosis Analysis Using Colony
Forming Units
THP-1 cells were seeded at 7 × 105 cells/well in 12 well plates
(Nunc) and were stimulated to adhere by adding 100 ng/ml of
phorbol 12-myristate 13-acetate (PMA) (Sigma-Aldrich) and left
to incubate for 48 h. Cells were then washed once with plain
RPMI 1640 (serum free, antibiotic free) and then incubated
overnight with fresh cRPMI. Cells were then washed once with
plain RPMI 1640 and then incubated in 400 µl of plain RPMI
1640 for at least an hour before adding the bacteria.
M. bovis BCG cells were grown to mid exponential growth
phase and 2ml were harvested by centrifugation and washed in
PBS.M. bovis BCG cells were then treated with or without human
serum, prior to incubation with rfBC. For serum treatment,
bacteria were resuspended in a 1/50 dilution of human serum
in 200 µl of DGVB++ buffer (2.5mM veronal buffer, pH 7.3,
72mM NaCl, 140mM glucose, 0.1% gelatin, 1mM MgCl2, and
0.15mM CaCl2) and incubated for 2 h at 37
◦C. Bacterial pellets
were then collected by centrifugation and washed once with PBS.
Complement activation by M. bovis BCG was confirmed using
complement consumption assays as described previously (24).
The bacterial cell pellets (serum and non-serum treated)
containing ∼2 × 109 bacteria were then resuspended in 1ml
plain RPMI 1640 with 5mM CaCl2. Bacteria were separated into
a single cell suspension by passing through a 1ml syringe with
25-gauge needle 12–15 times to break clumps. Tubes containing
the bacterial suspension were then set up and incubated with 0,
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10, 20, and 40µg/ml of rfBC, for 1 h at 37◦C, followed by 1 h at
4◦C, with gentle shaking.
Bacterial cell pellets were then collected via centrifugation
and resuspended in 2ml of fresh plain RPMI 1640. Then, 70 µl
of bacterial suspension [equivalent to a multiplicity of infection
(MOI) of 10:1, bacterial to macrophage] was added to each well
containing the THP-1 cells. The medium was mixed by gently
pipetting up and down 5 times. Plates were incubated at 37◦C at
5% CO2 at 3, 6, 24, and 48 h timepoints.
After each time point, supernatants were collected from
each well and stored at −20◦C. Wells were washed 3 times
with plain RPMI 1640 to remove any extracellular bacteria.
THP-1 cells were removed using 1ml of 0.25% trypsin and
pelleted using centrifugation. For each time point, THP-1 cell
pellets were then frozen at −80◦C for RNA extraction and also
analyzed for ingested mycobacteria as follows: THP-1 cells were
lysed by re-suspending the cell pellets in 1ml of 0.1% saponin
followed by a series of vortexing for 10min at room temperature.
Plates containing Middlebrook 7H10 agar with supplements
were prepared and four serial 1/10 dilutions of the cell lysate
were made. Next, 10 µl of the concentrated mycobacterial
suspension and diluted suspensions from each time-point were
spotted onto the 7H10 agar plates. The plates were secured
with parafilm and wrapped in aluminum foil, inverted and
incubated at 37◦C at 5% CO2 for 2–3 weeks. Bacterial CFU were
then counted. Assay was performed in triplicate for each rfBC
concentration and time point. Experiments were repeated three
times.
Phagocytosis Analysis Using Fluorescence
Microscopy
THP-1 cells were seeded at 1 × 105 cells on sterile coverslips
(Sigma-Aldrich) in 12 well plates and were induced to adhere
with PMA, incubated and washed, as described above. THP-1
cells were placed in 400 µl of plain RPMI 1640 for at least an
hour before adding the bacteria. GFP-expressing M. bovis BCG
was grown to mid exponential phase and harvested to obtain
1 × 109 bacteria/ml. Mycobacteria were prepared as previously
described for incubation with serum (complement deposition)
and without serum. Bacterial pellets were dissolved in 200 µl of
7H9 medium with supplements and 5mM CaCl2 and rfBC was
added at final concentrations of 0, 10, 20, and 40µg/ml. Samples
were incubated at 37◦C for 1 h followed by 1 h at 4◦C with gentle
shaking. Cells were then pelleted and resuspended in 2ml of
plain RPMI 1640. Next, 7 µl of the bacterial suspension from
each of the rfBC concentrations was added to wells containing
the THP-1 cells, giving a MOI of 10:1 bacteria to macrophages.
Wells were mixed gently by pipetting up and down 5 times. Plates
were incubated at 37◦C and in 5% CO2 for 3 h. Supernatants
were then discarded from wells and coverslips were washed 3
times with PBS. Cells were fixed in 4% paraformaldehyde at room
temperature for 10min and then washed a further three times in
PBS. Cells were then stained with Hoechst (Thermo Scientific)
(1:10,000 in PBS) and Alexafluor 546-conjugated wheat germ
agglutinin (WGA) (Thermo Scientific) (1:500 in PBS) for 10min
at room temperature in the dark. Coverslips were then washed
5 times in PBS and mounted onto glass slides with 1 drop of
anti-fade (Citifluor AF3) PBS solution.
To observe nuclear translocation of NF-κB, 1 × 105 THP-
1 cells per 13mm coverslip were differentiated with PMA,
and incubated with GFP-M. bovis BCG only, complement-
deposited GFP-M. bovis BCG, GFP-M. bovis BCG pre-treated
with 40µg/ml of rfBC, or complement-deposited GFP-M. bovis
BCG pre-treated with 40µg/ml of rfBC. Samples were incubated
in 500 µl of serum-free RPMI 1640 medium for 3 h. THP-1 cells
only were used as a negative control. Following fixation, cells
were permeabilized in 20mM HEPES-NaOH pH 7.4, 300mM
sucrose, 50mM NaCl, 3mM MgCl2, 0.5% Triton X-100 and
10% sodium azide for 5min on ice. Cells were then stained
with rabbit anti-NF-κB p65 polyclonal antibodies (1:500, Santa
Cruz Biotech), followed by Cy-3 goat anti-rabbit antibody (1:500,
Sigma). Cells were mounted using Vectashield antifade with
DAPI (Vector Labs) to reveal nuclei.
All Slides were observed under a Leica DM4000 fluorescence
microscope at ×40 magnification. Images were processed using
Image J software (https://imagej.nih.gov/ij/).
Total RNA Preparation and cDNA Synthesis
THP-1 cell pellets were collected and lysed as described above.
RNA extraction was performed using the GenElute Mammalian
Total RNA Purification Kit (Sigma-Aldrich) according to the
manufacturer’s protocol. Samples were then treated with DNase
(Sigma-Aldrich) to remove contaminating DNA according to the
manufacturer’s protocol. Samples were heated at 70◦C for 10min
to inactivate DNase I and the RNase, and subsequently chilled
on ice. The amount of RNA was measured using a NanoDrop
2000/2000c spectrophotometer (Thermo Fisher Scientific) at
260 nm and the ratio of absorbance at 260 nm and 280 nm was
used to assess the purity of the RNA. cDNAwas synthesized using
High Capacity RNA to cDNAKit (Applied Biosystems) following
the manufacturer’s protocol.
qPCR Assay for Cytokine Expression and
Data Analysis
The following oligonucleotide primers were used: 18S forward
(5′-ATGGCCGTTCTTAGTTGGTG-3′) and 18 S reverse (5′-
CGCTGAGCCAGTCAGTGTAG-3′); IL-1β forward (5′-GGA
CAAGCTGAGGAAGATGC-3′) and IL-1β reverse (5′-TCG
TTATCCCATGTGTCGAA-3′); IL-6 forward (5′-GAAAGCAGC
AAAGAGGCACT-3′) and IL-6 reverse (5′-TTTCACCAGGCA
AGTCTCCT-3′); IL-10 forward (5′-TTACCTGGAGGAGGT
GATGC-3′) and IL-10 reverse (5′-GGCCTTGCTCTTGTT
TTCAC-3′); IL-12 forward (5′-AACTTGCAGCTGAAGCCA
TT-3′) and IL-12 reverse (5′-GACCTGAACGCAGAATGTCA-
3′); TGF-β forward (5′-GTACCTGAACCCGTGTTGCT-3′) and
TGF-β reverse (5′-GTATCGCCAGGAATTGTTGC-3′); TNF-
α forward (5′-AGCCCATGTTGTAGCAAACC-3′) and TNF-
α reverse (5′-TGAGGTACAGGCCCTCTGAT-3′). PCR was
performed on all cDNA samples to assess the quality of the
cDNA. The qPCR assay was performed for the expression of pro-
and anti-inflammatory cytokines. The qPCR reaction consisted
of 5 µl Power SYBR Green MasterMix (Applied Biosystems),
75 nM of forward and reverse primer and 500 ng template
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cDNA in a 10 µl final reaction volume. PCR was performed in
a StepOne Plus Real-Time PCR System (Applied Biosystems).
The initial steps were 2min incubation at 50◦C followed by
10min incubation at 95◦C, the template was then amplified for
40 cycles under these conditions: 15 s incubation at 95◦C and
1min incubation at 60◦C. Samples were normalized using the
expression of human 18 S rRNA. Data was analyzed using the
StepOne software v2.3 (Applied Biosystems). Ct (cycle threshold)
values for each cytokine target gene were calculated and the
relative expression of each cytokine target gene was calculated
using the Relative Quantification (RQ) value, using the formula:
RQ = 2−11Ct and comparing relative expression with that of
the 18 S rRNA constitutive gene product. Assays were conducted
twice in triplicate.
Multiplex Analysis
Supernatants were collected from the phagocytosis assays at 24
and 48 h to measure secreted cytokines (IL-6, IL-10, IL12p40,
IL12p70, IL-1α, IL-1β, TNF-α, IL-13, IL-15, IL-17A, IL-9, TNF-
β), chemokines (MCP-3, MDC, Eotaxin, Fractalkine, GRO, IL-
8, IP-10, MCP-1, MIP-1α), growth factors (IL-2, EGF, FGF-
2, G-CSF, GM-CSF, IL-3, IL-4, IL-5, IL-7, VEGF) and other
ligands, cytokines and receptors (IFNA2, IFN-γ, FLT-3L, IL-
1RA, sCD40L). MagPix Milliplex kit (EMD Millipore) was
used to measure cytokine response following the manufacturer’s
protocol. 25 µL of assay buffer was added to each well of a
96-well plate, followed by the addition of 25 µL of standard,
controls or supernatants of cells treated withM. bovis BCG in the
presence or absence of rfBC and complement. 25 µL of magnetic
beads coupled to analytes of interest were added in each well
and incubated for 18 h at 4◦C. The 96-well plate was washed
with the assay buffer and 25 µL of detection antibodies were
incubated with the beads for 1 h at room temperature. 25 µL
of Streptavidin-Phycoerythrin was then added to each well and
incubated for 30min at room temperature with shaking at 750
rpm. Following a washing step, 150 µL of sheath fluid was added
to each well and the plate was read using the Luminex Magpix
instrument. Assays were conducted in duplicate.
Statistical Analysis
Analysis of data for statistical significance was conducted using
GraphPad Prism 6 for Windows (GraphPad Software, Inc.).
Statistical analyses were made using a one-way ANOVA test.
FIGURE 1 | Expression and purification rfBC. (A) Recombinant bovine conglutinin (rfBC) containing the homotrimeric neck and CRD regions was expressed in E. coli
BL21(λDE3) pLysS. 3 h after induction with 0.4mM IPTG, rfBC accumulated as an over-expressed protein of ∼23 kDa (lane 3) compared to uninduced cells (lane 2)
and was observed as inclusion bodies (lane 4). Samples were resolved on a SDS-PAGE (12% w/v gel), followed by Coomassie staining. Protein marker (lane 1). (B)
Purification of rfBC from inclusion bodies (lane 2) using denaturing and refolding in urea, followed by affinity chromatography on an agarose-N-acetylglucosamine
column. The affinity-purified rfBC (Lane 3), was made LPS-free prior to use (lane 4). Samples were resolved on a SDS-PAGE (12% w/v gel), followed by Coomassie
staining. Protein marker (lane 1). (C) Purified LPS-free rfBC verified by 12% SDS-PAGE, with 20µg/ml of protein loaded in triplicate (lanes 2, 3, and 4), together with a
negative control of 5µg/ml of maltose binding protein (MBP) loaded also in triplicate (lanes 5, 6, and 7). Lane 1 is protein marker. (D) Western blot analysis confirms
the identity and purity of rfBC (lanes 2, 3, and 4), using rabbit anti-bovine conglutinin. Western blotting with anti-MBP (not shown) confirmed no reaction with rfBC and
reaction with 42.5 kDa MBP. (E) Chemical cross-linking of purified rfBC to show that it could form dimeric and trimeric structures. 20µg/ml of rfBC were incubated with
1mM BS3 [bis(sulfosuccinimidyl)suberate] for 0min (lane 1), 1min (lane 2), 2min (lane 3), 4min (lane 4), 8min (Lane 5), 16min (Lane 6), 32min (lane 7), 64min (lane 8).
Protein marker (lane 9). Samples were resolved on a SDS-PAGE (12% w/v gel) followed by Coomassie staining and show dimers at 46 kDa and trimers at 69 kDa.
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FIGURE 2 | rfBC binds to M. bovis BCG. (A) rfBC binding to M. bovis BCG cells in the presence of Ca2+ with EDTA and maltose-binding protein used as negative
controls. Two-fold serial dilutions of rfBC were performed in 40mM Tris-HCl, 200mM NaCl, pH 7.4 containing 5mM CaCl2 or 10mM EDTA and added to the
mycobacteria and allowed to incubate for 2 h. This was followed by incubation with rabbit anti-bovine conglutinin antibody or mouse anti-MBP monoclonal antibody.
Then, protein A-HRP was added and developed with the substrate 3, 3′,5,5′-Tetramethylbenzidine (TMB) and the color read at 450 nm. All assays were conducted in
triplicate. (B) Direct binding of 20µg/ml of rfBC to M. bovis BCG, with 20µg/ml of MBP as a negative control. Cells were incubated for 2 h with either rfBC or MBP,
followed by incubation with rabbit anti-bovine conglutinin antibody or mouse anti-MBP monoclonal antibody. Bacterial cells were then washed, fixed and stained with
protein A conjugated with fluorescein isothiocyanate (FITC). Bar scale: 10µm. (C) Competitive inhibition of rfBC binding to M. bovis BCG by maltose. rfBC was
pre-treated with either 10 or 100mM of maltose for 1 h before incubating with M. bovis BCG. Binding of rfBC was detected as described above. The percentage
difference in rfBC binding for was calculated with respect to untreated 40µg/ml of rfBC + M. bovis BCG (100%). Assay was conducted in triplicate. Bars denote ± 2
standard deviations. A one-way ANOVA test was performed on the data to determine significant differences in binding between M. bovis BCG + 40µg/ml of rfBC
(untreated) and 10 and 100mM maltose. Both comparisons were significant (**p ≤ 0.01).
P-values <0.05 were considered statistically significant, unless
otherwise stated (ns, non-significant).
RESULTS
Expression, Purification and
Characterization of rfBC
We expressed and purified a 154 amino acid long, recombinant
fragment of conglutinin (rfBC), as previously described (13).
rfBC is composed of the α-helical neck region (amino acids
197–224) and the C-terminal CRD region (amino acids 225–
351) of the native mature protein. The protein was expressed
successfully in E. coli (Figure 1A) and then purified from
inclusion bodies yielding a band of 23 kDa on an SDS-PAGE gel
(Figure 1B). Immunoblotting was performed using a rabbit anti-
conglutinin antibody to confirm the identity of the 23 kDa band
(Figures 1C,D). To further verify that rfBC was correctly folded
and formed a homotrimer in solution, chemical cross-linking
using BS3 was performed on the purified protein. rfBC formed
trimers in a time- and BS3 concentration-dependant manner
(Figure 1E).
rfBC Binds to Mycobacteria
rfBC bound to M. bovis BCG in a calcium dependent manner
(Figures 2A,B); binding in the presence of 5mM EDTA was
reduced 3- to 4-fold, whilst negligible binding was seen with
MBP, used as a negative control protein (Figures 1A,B). The
interaction between rfBC and M. bovis BCG reached saturation
at 20µg/ml of rfBC (Figures 2A,B); the concentration is
comparable to serum levels of conglutinin in B. taurus of
12µg/ml (4). Maltose, a glucose-glucose disaccharide analogous
to mannose, was shown to inhibit the interaction of rfBC with
M. bovis BCG, suggesting competitive inhibition of binding to
surface motifs, such as LAM (Figure 2C). Furthermore, maltose
has been shown to have similar inhibitory characteristics to
mannose in our previous work (13). Maltose has previously been
shown to inhibit the binding of SP-D to surface ligands (2–4).
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FIGURE 3 | rfBC has a direct bacteriostatic effect on the growth of M. bovis BCG. (A) M. bovis BCG cells were grown in the presence of 10, 20, and 40µg/ml of rfBC
to assess any effect on bacterial growth. Untreated M. bovis BCG was used as a negative control. Bacterial colony forming units were obtained and counted. The
percentage difference in growth for each rfBC concentration was calculated with respect to untreated M. bovis BCG as 100% (corresponding to 6 × 104 cells). Bars
denote ± 2 standard deviations. The experiment was performed in triplicate for each rfBC concentration and was repeated three times. A one-way ANOVA test was
performed to determine significant differences in growth from untreated M. bovis BCG vs. treatment with rfBC at the different concentrations. All comparisons were
significant (**p ≤ 0.01). (B) Propidium iodide (PI) assay was used to assess any bacterial cell lysis as a result of incubation with rfBC. M. bovis BCG cells were
incubated for 2 h with 0, 10, 20, and 40µg/ml of rfBC. Heat-treated M. bovis BCG was used as a positive control for cell lysis. PI was added, and cells spotted onto
glass slides and analyzed using fluorescence microscopy. Fluorescent M. bovis BCG cells were counted from each sample and the total percentage of PI stained cells
calculated for each rfBC concentration. Bars denote ± 2 standard deviations. The assay was performed in triplicate. A one-way ANOVA test was performed to
determine significant differences in PI staining from heat-treated M. bovis BCG vs. treatment with rfBC at the different concentrations. All comparisons were significant
(p ≤ 0.05), unless where shown (ns, not significant; p > 0.05). (C) Qualitative data showing PI staining of M. bovis BCG at 40µg/ml of rfBC, compared to heat-treated
M. bovis BCG and untreated M. bovis BCG. Bar scale 10µm.
rfBC has a Direct Bacteriostatic Effect on
Mycobacterial Growth
rfBC was observed to have a direct inhibitory effect on
the in vitro growth of M. bovis BCG (Figure 3A). rfBC
brought about significant reduction in M. bovis BCG growth
that was 30% at 10µg/ml and 90% at 40µg/ml of rfBC,
compared to rfBC-untreated M. bovis BCG (Figure 3A). This
direct effect was also observed to be bacteriostatic in nature,
rather than bactericidal, as virtually no bacterial cell lysis was
observed on rfBC-treated M. bovis BCG, as determined by
propidium iodide (PI) staining (Figures 3B,C). These results
appear to suggest that conglutinin may be of importance
in the control of systemic mycobacterial infection in B.
taurus.
rfBC Inhibits Uptake of M. bovis BCG by
THP-1 Cells
rfBC-treated M. bovis BCG showed reduced uptake by THP-
1 cells, compared to untreated M. bovis BCG, with up to 65%
inhibition (40µg/ml of rfBC) (Figure 4). Since conglutinin is an
iC3b-binding collectin, we also examined how it affected uptake
of complement-treated M. bovis BCG. In this case, M. bovis
BCG was incubated with human serum as a complement source,
washed and then allowed to bind rfBC. Although complement
treatment ofM. bovis BCG resulted in enhanced phagocytosis (by
∼ 22%) compared to untreated M. bovis BCG, we also observed
marked inhibition in the phagocytosis of rfBC + complement-
treated M. bovis BCG. This had a greater inhibitory effect
than just treatment by rfBC alone (80% reduction in uptake
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FIGURE 4 | rfBC mediated inhibition of phagocytosis of M. bovis BCG by
THP-1 cells, with and without complement deposition and its effect on the
pro-inflammatory response. M. bovis BCG cells were pre-treated with human
serum to induce complement deposition. M. bovis BCG cells with and without
complement deposition were then treated with rfBC at concentrations of 0,
10, 20, and 40µg/ml for 2 h. The M. bovis BCG cells were then incubated with
THP-1 cells for 3 h. After THP-1 cell lysis, phagocytosed M. bovis BCG were
measured by plating lysate on 7H10 media to obtain colony forming units
(CFUs). The percentage difference in uptake of M. bovis BCG by THP-1 cells
for each rfBC concentration was calculated with respect to untreated M. bovis
BCG as 100% (corresponding to 4 × 104 cells). Bars denote ± 2 standard
deviations. The experiment was performed three times in triplicate. A one-way
ANOVA test was performed on the data to determine significant differences in
uptake from untreated M. bovis BCG vs. treatment with rfBC, complement
only and complement plus rfBC. All comparisons were significant (**p ≤ 0.01).
at 40µg/ml) (Figure 4). Fluorescence microscopy data also
corroborated the inhibitory effect of rfBC on the phagocytosis
of M. bovis BCG with and without complement deposition
on the bacteria (Figures 5, 6). Thus, rfBC exhibits its uptake
inhibitory effect both in the absence and presence of complement
deposition.
rfBC Dampens the Pro-Inflammatory
Response During Phagocytosis
We examined the early stages of the inflammatory response
by measuring the mRNA expression levels of pro- and anti-
inflammatory cytokines (Figure 7). These data show that rfBC-
treated M. bovis BCG elicited a down-regulation of the pro-
inflammatory cytokines (TNF-α, IL-1β, IL-6 and IL-12), at both
3 and 6 h of incubation with THP-1 macrophages. The effect
on TNF-α is particularly dramatic. These levels in cytokine
expression were compared to THP-1 cells only with no treatment
with rfBC or M. bovis BCG only. In contrast, the anti-
inflammatory cytokine TGF-β showed an increase in expression
in the presence of rfBC-treatedM. bovis BCG. However, the other
anti-inflammatory cytokine, IL-10, was also down-regulated
during these initial hours of interaction. THP-1 cells incubated
only with rfBC did not show any significant changes in cytokine
expression (Figure 7).
We also examined the immune response after 24 h of
phagocytosis using multiplex cytokine array analysis to measure
the protein levels of cytokines and chemokines produced by
THP-1 cells in the supernatant. We observed that rfBC-treated
M. bovis BCG triggered a broad decrease in the levels of pro-
inflammatory cytokines (TNF-α, IL-1α, IL-1β, IL-6, IL-12p40),
compared to untreated M. bovis BCG (Figure 8). A similar
decrease in levels was also observed for the chemotractant
MCP-1 and growth factors (VEGF, GM-CSF, and GRO), further
suggesting a dampening of pro-inflammatory responses. The
decrease in levels of IL-12p40 by rfBC also points to a
possible suppression of Th1 cytokines that can be produced by
CD4+ T-cells, leading to a reduction in IFN-γ which is also
critical for sustained intracellular killing by macrophages and
granuloma formation. The decrease of IL-10 by rfBC suggests the
suppression of anti-mycobacterial responses by the macrophage.
The increase in uptake of complement-treated M. bovis BCG
compared to untreatedM. bovis BCG (Figure 4), coincided with
an enhancement of the pro-inflammatory response (Figures 8,
9A–D). In particular, TNF-α, IL-1β, IL-6, and IL-12p40 were
significantly elevated. In contrast, for the anti-inflammatory
cytokine IL-10, no significant change in levels was observed. This
observed enhancement of the pro-inflammatory response was
also maintained during the uptake of rfBC+complement-treated
M. bovis BCG (Figure 8).
The increase in pro-inflammatory cytokines (e.g., TNF-α)
after the initial stages of phagocytosis of mycobacteria by
macrophages is thought to be particularly crucial for the killing
of intracellular mycobacteria and for the formation of the
protective granuloma and is observed in the untreated M. bovis
BCG (Figure 8). Furthermore, TNF-α production was enhanced
further in complement-deposited M. bovis BCG (Figure 8).
Intriguingly, rfBC does not seem to have a noticeable effect on
the inflammatory response of complement-deposited M. bovis
BCG (i.e., M. bovis BCG + complement + rfBC), suggesting
that any phagocytosis ofM. bovis BCG that has occurred may be
exclusively via complement receptors and this may be sufficient
to mount an optimum inflammatory response.
Further evidence in support of dampening of the pro-
inflammatory response is shown by the NF-κB nuclear
translocation in response to complement-deposited M. bovis
BCG, showing an increase in the levels of pro-inflammatory
cytokines, which seems to be restricted in response to rfBC
+ complement bound M. bovis BCG, (Figure 10). Since NF-
κB is a key transcription factor that regulates the expression
of a number of pro-inflammatory cytokines, we studied the
translocation of NF-κB in THP-1 cells stained with an antibody
against the p65 subunit of NF-κB and performed analysis using
fluorescence microscopy. We observed that NF-κB translocation
was more pronounced in complement-treated M. bovis BCG
and rfBC + complement-treatedM. bovis BCG, when compared
to the control (THP-1 cells only) (Figure 10). Similar levels
of NF-κB translocation were also observed in untreated M.
bovis BCG. However, virtually no translocation was observed for
rfBC-treated M. bovis BCG, thus explaining the downregulation
of pro-inflammatory cytokines (TNF-α, IL-1β, and IL-6) and
chemokines (IL-8, MCP-1, and IP-10) (Figures 4, 9A,B).
We also observed that the ability of rfBC to suppress pro-
inflammatory cytokines appeared to be transient as it recovered
somewhat after 48 h, to levels observed for untreated M. bovis
BCG (Figures 9A–D). A number of other secreted cytokines,
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FIGURE 5 | rfBC mediated inhibition of phagocytosis of M. bovis BCG by THP-1 macrophages. Differential phagocytosis of GFP-M. bovis BCG by THP-1
macrophages after treatment with 0, 10, 20, and 40µg/ml of rfBC. Cells were incubated for 3 h. Cells were washed, fixed and stained with Alexafluor 546-conjugated
wheat germ agglutinin to reveal the plasma membrane (red) and the nucleus was strained with Hoechst (blue). Images are shown as single sections; Arrows show foci
of M. bovis BCG bacteria. bar scale 10µm.
chemokines, growth factors, ligands and receptors were also
examined which suggested an anti-inflammatory effect by rfBC
(Figures 9A–D). Coupled together, these data suggest that
conglutinin has an anti-inflammatory effect that may suppress
anti-mycobacterial immunity and promote the extracellular
persistence of theM. bovis pathogen in B. taurus.
DISCUSSION
In the present study, we have studied the intriguing bovine
collectin, conglutinin, and its possible role in tuberculosis host-
pathogen interactions. We have used M. bovis BCG as a
model for M. bovis and M. tuberculosis and demonstrate that
a homotrimeric recombinant truncated form of conglutinin
(rfBC), composed of the α-helical neck region and the CRD
(13), was able to bind to M. bovis BCG and had a major
influence on its phagocytosis by THP-1 macrophages. We
also show that this interaction can occur with and without
complement deposition on the bacterium, although complement
treatment profoundly altered the host’s inflammatory response.
rfBC significantly inhibited the uptake of M. bovis BCG by
THP-1 cells and this occurred in a dose-dependent manner. In
contrast, complement deposition enhanced uptake of M. bovis
BCG by THP-1 macrophages, but when these mycobacteria
were treated with rfBC, significant inhibition of uptake
was also observed. Our recent studies have also highlighted
similar inhibitory effects by complement regulatory proteins
(factor H and properdin) on the phagocytosis of M. bovis
BCG by THP-1 macrophages (34, 35). These observations
suggest that conglutinin is masking mycobacterial ligands and
inhibiting uptake, possibly through mannose receptors, but
also is masking interactions with complement by binding
to iC3b and inhibiting uptake though complement receptors
(e.g., CR3). These data are the first to show an anti-
opsonic effect of conglutinin on mycobacteria and that this
can occur in a complement dependent and independent
manner.
Conglutinin is a member of the collectin protein family
which are soluble PRRs that are able to bind to oligosaccharide
and glycolipid structures (PAMPs) on the surface of microbes.
Conglutinin is known to have antimicrobial properties, being
able to opsonise and inhibit haemagglutination of influenza
A virus and binds to rotavirus, E. coli and S. typhimurium
as well as LPS (8, 10–13). However, conglutinin’s role in
bovine tuberculosis has not been extensively explored. This is
of particular importance since conglutinin is found in Bovidae
species (e.g., cattle: B. taurus) (2). Bovine tuberculosis (M. bovis
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FIGURE 6 | rfBC mediated inhibition of phagocytosis of complement-treated M. bovis BCG by THP-1. Differential phagocytosis of complement-treated GFP-M. bovis
BCG by THP-1 macrophages after treatment with 0, 10, 20, and 40µg/ml of rfBC. Cells were incubated for 3 h. Cells were washed, fixed and stained with Alexafluor
546-conjugated wheat germ agglutinin to reveal the plasma membrane (red) and the nucleus was strained with Hoechst (blue). Images are shown as single sections;
Arrows show foci of M. bovis BCG bacteria. Bar scale 10µm.
infection) remains not just a significant agricultural economic
problem in the UK and worldwide, but is also an important
zoonosis affecting a wide range of domestic and wild animals,
and including humans (20–23). We observed that rfBC bound
to M. bovis BCG and that this binding was dose dependent,
reaching saturation of binding at 20µg/ml of rfBC, which is
similar to the serum levels of conglutinin observed in cattle
(4). Binding of rfBC to M. bovis BCG was observed to be
greater in the presence of Ca2+ than in the presence of EDTA.
This is the first definitive observation of conglutinin pattern
recognition and binding to a Gram-positive bacterium (e.g.,
mycobacteria). SP-D has also recently been shown to bind to
M. bovis BCG (36). The mycobacterial ligand for conglutinin is
likely to be those reported for SP-D and M. tuberculosis, namely
the terminal dimannosyl units of lipoarabinomannan (LAM)
(37, 38), since SP-D is structurally similar to conglutinin (2)
and M. bovis BCG shares an almost identical bacterial surface,
including LAMs (39, 40). We observed that rfBC binding to
M. bovis BCG was inhibited when rfBC was pre-treated with
maltose. Maltose has been shown to be an effective inhibitor
of conglutinin and rfBC binding to surface ligands (2, 13). The
results show that maltose was able to block the CRD region of
rfBC preventing interaction with sugar moieties, such as LAM
on the surface of the mycobacterium. These observations are
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FIGURE 7 | Temporal expression of cytokines by THP-1 cells incubated with M. bovis BCG and different concentrations of rfBC. qPCR analysis of the expression of
cytokines (TNF-α, IL-1β, IL-6, IL-10, TGF-β, and IL-12) at 3 and 6 h incubation. The calibrator sample used was THP-1 cells only. The data was normalized to 18S
rRNA gene expression which was used as an endogenous control. Assays were conducted in triplicate. The RQ value was calculated using the formula: RQ =
2−11Ct. Error bars represent ± standard error of the mean. A 2-way ANOVA was performed on the data to compare differences in expression for each cytokine (e.g.,
between zero and different concentrations of rfBC added to M. bovis BCG). All comparisons are statistically significant (p ≤ 0.05), except where shown (ns, not
significant).
in agreement with results from our previous work that showed
various sugars were also able to bind to the CRD region of rfBC
and that these specificities are similar for full length conglutinin
(2, 13).
We also observed that rfBC could directly inhibit the growth
of M. bovis BCG in vitro in a dose-dependent manner. The
mechanism of inhibition is not known, but it is clear that
this inhibition is bacteriostatic, rather bacteriocidal (e.g., no
bacterial cell lysis was observed in rfBC treated mycobacteria).
To our knowledge, this is the first demonstration of a
direct bacteriostatic effect by a collectin on a Gram-positive
bacterium. Previous studies have shown growth inhibition
in Gram-negative bacteria by SP-A and SP-D by increased
membrane permeability, but this was also not bacteriocidal
(41–43). No evidence of agglutination of M. bovis BCG
was observed by rfBC. This is because, unlike the native
conglutinin dodecameric form which is multivalent with respect
to the trimeric CRDs, rfBC is only trivalent with respect
to CRDs and lacks the long rigid collagen-like region so is
unable to form the cruciform structure that allows for greater
bridging interactions between the bacteria. These observations
support similar findings on the aggregation properties of
SP-D and its truncated recombinant form rhfSP-D (32,
44).
Our data also shows that conglutinin does not enhance
interactions of mycobacteria with macrophages, but actually
plays a role in reducing this interaction. This observation has
also been described for SP-D and mycobacteria and this reduced
interaction is also independent of any bacterial agglutination
(32). Similar to SP-D (32), we found conglutinin to be able to
significantly inhibit the uptake of mycobacteria by macrophages
(THP-1 cells), possibly by altering the usual interaction between
the ligands on the mycobacterial surface and receptors on the
macrophage. The main routes for M. tuberculosis phagocytosis
by macrophages is via the mannose receptor and complement
receptors (26, 45–47). Based on our study, we consider that
conglutinin may intefere with both these interactions. Firstly, like
SP-D, it is likely that conglutinin binds to the terminal mannosyl
units of LAM on M. bovis BCG, which are ligands for the
mannose receptor, and that this interaction is reducing the uptake
ofM. bovis BCG by conglutinin binding to LAM on the bacterial
surface and blocking its interaction with the mannose receptor
on macrophages. We have indeed observed a marked inhibition
by rfBC of M. bovis BCG phagocytosis by THP-1 macrophages
and this is dose-dependent and the inhibitory effect is greater
than that observed for SP-D (32). Secondly, we investigated the
effect of complement and how conglutinin may influence the
interaction between mycobacteria and macrophages. Previous
studies have shown the deposition of complement component C3
on mycobacteria and its role in the uptake of the pathogen via
complement receptors CR1, CR3, and CR4 on the macrophage
(26–31). C3 binding to M. tuberculosis and M. bovis BCG has
Frontiers in Immunology | www.frontiersin.org 12 February 2019 | Volume 9 | Article 3159
Mehmood et al. Interaction Between Conglutinin and BCG
FIGURE 8 | Multiplex cytokine analysis of supernatants collected at 24 h after phagocytosis of M. bovis BCG by macrophages incubated with rfBC and complement
plus rfBC. Using multiplex analysis, the supernatants were measured for the levels of cytokines, chemokines and growth factors after 24 h of phagocytosis. Bars
denote ± 2 standard deviations. Assays were performed in duplicate. A one-way ANOVA test was performed on the data to determine significant differences in
cytokine/chemokine production after phagocytosis of untreated M. bovis BCG, vs. treatment with 40µg/ml of rfBC, complement only and complement plus 40µg/ml
of rfBC. All comparisons were significant (**p ≤ 0.01), unless otherwise shown (ns: p > 0.05).
been shown to occur via the three complement pathways and C3
is present on the bacteria in the forms C3b and iC3b (24, 27). C3b
is necessary for the complement cascade to progress toward the
terminal membrane attack complex (MAC), but iC3b is not and
cannot take part in this reaction. Furthermore, C3b is a ligand for
CR1, whilst iC3b is a ligand for CR3 and CR4 (48). iC3b is formed
on the surface of microbes from C3b, by cleavage by factor I
together with cofactors like factor H and CR1 (49). We have
observed that complement-depositedM. bovis BCG are inhibited
from phagocytosis by THP-1 macrophages by rfBC. Conglutinin
is a known unique binder of iC3b, as it has a selective affinity for
the mannose oligosccharides in the α-chain of iC3b (14). Thus, a
likely mechanism of this inhibition is the binding of conglutinin
to iC3b deposited on the bacterial surface, blocking phagocytosis
via macrophage receptors CR3 and CR4. In contrast, we observed
an enhancement of phagocytosis by complement-deposited M.
bovis BCG by THP-1 macrophages without the presence of rfBC,
compared to M. bovis BCG only, demonstrating likely enhanced
uptake by CR1, CR3, and CR4. Consequently, conglutinin
significantly inhibits uptake ofM. bovis BCG bymacrophages in a
complement dependent and complement-independent manner,
blocking host-bacterial interactions via complement receptors
and mannose receptor, respectively. To our knowledge, this is the
first reported observation of mycobacterial phagocytosis being
blocked via two distinct mechanisms by a single collectin.
To investigate the role of conglutinin further in mycobacterial
infection, we examined the subsequent immune response by
THP-1 macrophages during phagocytosis. We observed that
M. bovis BCG, treated with rfBC, dampened pro-inflammatory
response after 24 h of phagocytosis, compared to M. bovis
BCG only, after a significant inhibition of bacterial uptake by
the macrophages. The pro-infammatory cytokine/chemokines
levels at 48 h were similar to levels observed for M. bovis
BCG only. In contrast, the pro-inflammatory response was
elevated significantly in complement-deposited M. bovis BCG
and complement-deposited M. bovis BCG treated with rfBC
and were at similar levels to M. bovis BCG only. However,
for complement-deposited M. bovis BCG treated with rfBC,
there was significant inhibition of phagocytosis, whilst for
complement-depositedM. bovis BCG there was an enhancement
of uptake.
In the bovine lung, it is not clear whether there are significant
local levels of conglutinin. One study has shown conglutinin
in lung macrophages, being localized to the phagolysosome,
but it is unclear whether this was internalized as a result
of phagocytosis, or synthesized locally, or if it is membrane
bound (50). SP-A and SP-D are also the main collectins
found in the lungs and have potent anti-microbial properties
(17). However, if conglutinin is present in the bovine lung,
then recruitment of conglutinin by mycobacteria may be
important in the initial stages of tuberculosis infection. After
inhalation, among the first host cells M. bovis encounters is the
alveolar macrophage and conglutinin inhibition of uptake of the
bacterium by macrophages may be protective. In vivo, alveolar
macrophages phagocytose mycobacteria, but ultimately fail to
destroy them and provide a niche for the bacteria to survive and
persist. Conglutinin may inhibit this and facilitate the exclusion
of the pathogen to an extracellular environment enhancing
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FIGURE 9 | Continued
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FIGURE 9 | Multiplex cytokine analysis of supernatants collected at 24 and 48 h after phagocytosis of M. bovis BCG by macrophages incubated with rfBC and
complement plus rfBC. The supernatants were collected from phagocytosis assay of M. bovis BCG in the presence or absence of rfBC and complement plus rfBC at
24 h and 48 h time points. The levels of cytokine production was measured for (A) (IL-6, IL-10, IL12p40, IL12p70, IL-1α, IL-1β, TNF-α, IL-13, IL-15, IL-17A, IL-9,
TNF-β), (B) chemokines (MCP-3, MDC, Eotaxin, Fractalkine, GRO, IL-8, IP-10, MCP-1, MIP-1α), (C) growth factors (IL-2, EGF, FGF-2, G-CSF, GM-CSF, IL-3, IL-7,
VEGF), and (D) related ligands and receptors (IFNA2, IFN-γ, FLT-3L, IL-1RA, sCD40L) using multiplex analysis. Error bars represent standard deviation. A one-way
ANOVA test was performed on the data to determine significant differences in expression of cytokine production from untreated M. bovis BCG vs. treatment with
rfBC, and M. bovis BCG treated with complement vs. treatment with complement plus rfBC. All comparisons were significant (p ≤ 0.05), unless where shown (ns, not
significant; p > 0.05). Supernatants were analyzed in duplicate.
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FIGURE 10 | Cytoplasm to nucleus translocation of NF-κB in THP-1 cells co-cultured with M. bovis BCG with or without rfBC/complement deposition. THP-1 cells
were incubated with GFP-M. bovis BCG pre-treated with 40µg/ml of rfBC, with and without complement deposition. These were compared to GFP-M. bovis BCG
only and complement-deposited GFP-M. bovis BCG only. THP-1 cells only were used as negative controls. Bacteria and THP-1 cells were incubated for 3 h for
phagocytosis to occur. Cells were washed, fixed, permeabilised and incubated with rabbit anti-NF-κB p65 antibodies, followed by Cy3-conjugated goal anti-rabbit
antibody (red). The nucleus was stained with DAPI (blue). Arrows highlight nuclear NF-κB in the merged images. Scale bar 20µm.
microbial clearence e.g., ciliary mucosa. The dampening of the
pro-inflammatory response by conglutinin may also supress
the production of important cytokines and chemoattractants
(TNF-α, IL-1β, IL-6, IL-12p40) that recuit inflammatory cells and
discourage inflammation and tissue remodeling necessary for
granuloma formation (51–54). In the absence of complement in
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the lungs, this may be a preferred stratergy by the host to protect
against mycobacterial infection. However, there is evidence of
complement in the lungs that could support C3 deposition
on mycobacteria (27). In this scenerio, conglutinin could be
acting once again to maintain the pathogen in the extracellular
milieu, while also simultaneously tailoring the enhanced pro-
inflammatory response to the extracellular environment for
clearance of the pathogen.
Conglutinin is primarily found in serum in the bovine host
and it is in this environment that it may play a crucial role.
Conglutinin is synthesized in the liver and secreted into the blood
plasma at a mean serum concentration of 12µg/ml (4), which is
similar to the molar concentrations of rfBC used in our study.
Interestingly, it has also been shown that low plasma levels of
conglutinin in cattle predispose to respiratory infection and the
basis for this was found to be genetic in some breeds (4). M.
bovis bacteremia in cattle appears to be rare with only a few cases
being reported (55–57). This may be due to an under-reporting
of such cases (58), or may be due to enhanced ability of the
bovine host to cope with disseminated infection and bacteremia.
It is plausible that conglutinin plays a major role in controlling
M. bovis bacteremia, since it is present in significant amounts
in the serum and low levels are linked with susceptibility to
infection (4). These reports on M. bovis bacteremia and the
findings from our study, point to an intriguing possibility that
conglutinin is involved, together with complement, in controlling
the dissemination ofM. bovis infection.
The macrophage is a natural environment for virulent
mycobacteria, but for many other pathogens entry into this
host cell is terminal. Factors that enhance phagocytosis of
mycobacteria into macrophages are likely to be harmful to the
host. We envisage that reducing macrophage phagocytosis and
growth of mycobacteria (M. bovis and M. tuberculosis) will
be protective for the host. Therefore, findings from our study
suggest that conglutinin plays an important host defense role
against bovine tuberculosis infection by inhibiting phagocytosis
of mycobacteria by macrophages via two key knownmechanisms
of interaction, i.e., the macrophage mannose receptor and
complement iC3b receptors. Conglutinin probably enhances
the clearance of mycobacterial infection by downplaying
pathogen immune evasion strategies and also augmenting
the pro-inflammatory response against infection by down-
regulating the cellular immune response against infection,
supressing tissue damage and steering toward the extracellular
clearance of the pathogen. This study provides insights
into previously unknown involvement of conglutinin and
mycobacterial infection. Further studies using pathogenic M.
bovis and M. tuberculosis in vitro (e.g., bovine macrophages)
and in vivo are needed to fully characterize the nature and
consequences of involvement of conglutinin in tuberculosis
pathogenesis.
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